Back to Authors

Fei, Peiwen

A5044157771 | I1331384533

Mayo Clinic

University of Hawaii System

Citations 9

Understanding Cancer Health Disparities

Cancers | February 2, 2026 | Volume: 18 | Issue: 3 | Pages: 476

10.3390/cancers18030476 | PMID 41681948

Cancer health disparities represent profound inequalities in incidence, outcomes, and survivorship across populations. While traditionally examined through distinct lenses of either molecular biology or social epidemiology, these disparities arise from the complex interplay of genetic susceptibility, epigenetic dysregulation, and social determinants of health (SDoH). This review proposes that DNA damage and genomic instability serve as a critical mechanistic bridge, integrating exposures from the societal level to cellular dysfunction. We synthesize evidence demonstrating how SDoH—such as systemic inequities, environmental exposures, and chronic stress—converge with genetic and epigenetic factors to disproportionately increase DNA damage burden, impair repair mechanisms, and accelerate tumorigenesis in marginalized communities. Using the elevated gastrointestinal cancer rates among Native Hawaiians and Pacific Islanders (NH/PI) as a case study, we illustrate how historical, environmental, and socioeconomic factors interact with biological pathways to drive disparities. The review highlights key advances in DNA damage research—from somatic mutation theory to the modern understanding of chronic genomic stress—and explores how innovations in single-cell genomics, biomarker discovery, and computational modeling can unravel disparity etiologies. We argue that a translational framework linking social exposure data to molecular biomarkers of DNA damage is essential for moving beyond descriptive disparities to mechanistic understanding. Ultimately, addressing cancer equity requires interdisciplinary strategies that bridge molecular oncology, public health, and community-engaged research, targeting the root causes where social inequities become biologically embedded as genomic instability.
DNA methylation at the vicinity of the proximal polyadenylation site in FANCD2 gene involves human malignancy

Cell Cycle | September 3, 2018 | Volume: 17 | Issue: 17 | Pages: 2204-2206

10.1080/15384101.2018.1516983 | PMID 30176149

FANCD2 and DNA Damage

International Journal of Molecular Sciences | August 21, 2017 | Volume: 18 | Issue: 8 | Pages: 1804

10.3390/ijms18081804 | PMID 28825622

Investigators have dedicated considerable effort to understanding the molecular basis underlying Fanconi Anemia (FA), a rare human genetic disease featuring an extremely high incidence of cancer and many congenital defects. Among those studies, FA group D2 protein (FANCD2) has emerged as the focal point of FA signaling and plays crucial roles in multiple aspects of cellular life, especially in the cellular responses to DNA damage. Here, we discuss the recent and relevant studies to provide an updated review on the roles of FANCD2 in the DNA damage response.
Overlooked FANCD2 variant encodes a promising, portent tumor suppressor, and alternative polyadenylation contributes to its expression

Oncotarget | February 3, 2017 | Volume: 8 | Issue: 14 | Pages: 22490-22500

10.18632/oncotarget.14989 | PMID 28157704

BLM promotes the activation of Fanconi Anemia signaling pathway

Oncotarget | April 12, 2016 | Volume: 7 | Issue: 22 | Pages: 32351-32361

10.18632/oncotarget.8707 | PMID 27083049

Distinct Metabolic Signature of Human Bladder Cancer Cells Carrying an Impaired Fanconi Anemia Tumor-Suppressor Signaling Pathway

Journal of Proteome Research | March 9, 2016 | Volume: 15 | Issue: 4 | Pages: 1333-1341

10.1021/acs.jproteome.6b00076 | PMID 26956768

A Hidden Role of the Inactivated FANCD2: Upregulating ΔNp63

Oncotarget | September 16, 2015 | Volume: 4 | Issue: 9 | Pages: 1416-1426

10.18632/oncotarget.1217 | PMID 23965832

Basal level of FANCD2 monoubiquitination is required for the maintenance of a sufficient number of licensed-replication origins to fire at a normal rate

Oncotarget | September 16, 2015 | Volume: 5 | Issue: 5 | Pages: 1326-1337

10.18632/oncotarget.1796 | PMID 24658369

Mutated Fanconi anemia pathway in non-Fanconi anemia cancers

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 24 | Pages: 20396-20403

10.18632/oncotarget.4056 | PMID 26015400